Belatacept in kidney transplantation

David Wojciechowski, Flavio Vincenti

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: In June 2011 the US Food and Drug Administration approved belatacept (Nulojix; Bristol-Myers Squibb, Princeton, New Jersey, USA) for the prophylaxis of organ rejection in adult kidney transplant recipients. This review will discuss the use of belatacept for the prevention of acute rejection as part of a maintenance immunosuppression regimen. RECENT FINDINGS: Belatacept is a selective costimulation blocker designed to provide effective immunosuppression while avoiding the toxicities associated with calcineurin inhibitors. Phase 3 trial data have demonstrated that belatacept is noninferior to cyclosporine in 1-year patient and allograft survival. Three-year data demonstrate an ongoing improvement in mean measured glomerular filtration rate in belatacept-treated versus cyclosporine-treated patients. Overall, there seemed to be an improvement in cardiometabolic parameters in patients treated with belatacept compared with cyclosporine. There was a trend toward higher rates of early rejection episodes in patients treated with belatacept. One safety issue that must be considered when using belatacept is the potential for increased risk of posttransplant lymphoproliferative disease, especially in Epstein-Barr virus-seronegative recipients or patients treated with lymphocyte-depleting agents. SUMMARY: Belatacept is the first new agent available in kidney transplant that may achieve the goal of improved long-term renal function.

Original languageEnglish (US)
Pages (from-to)640-647
Number of pages8
JournalCurrent Opinion in Organ Transplantation
Volume17
Issue number6
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Kidney Transplantation
Cyclosporine
Kidney
Immunosuppression
Abatacept
United States Food and Drug Administration
Human Herpesvirus 4
Glomerular Filtration Rate
Allografts
Maintenance
Lymphocytes
Transplants
Safety

Keywords

  • belatacept
  • costimulation
  • kidney transplant

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

Belatacept in kidney transplantation. / Wojciechowski, David; Vincenti, Flavio.

In: Current Opinion in Organ Transplantation, Vol. 17, No. 6, 01.12.2012, p. 640-647.

Research output: Contribution to journalReview article

Wojciechowski, David ; Vincenti, Flavio. / Belatacept in kidney transplantation. In: Current Opinion in Organ Transplantation. 2012 ; Vol. 17, No. 6. pp. 640-647.
@article{1f697e343f3749608f6e10fd9c735e46,
title = "Belatacept in kidney transplantation",
abstract = "PURPOSE OF REVIEW: In June 2011 the US Food and Drug Administration approved belatacept (Nulojix; Bristol-Myers Squibb, Princeton, New Jersey, USA) for the prophylaxis of organ rejection in adult kidney transplant recipients. This review will discuss the use of belatacept for the prevention of acute rejection as part of a maintenance immunosuppression regimen. RECENT FINDINGS: Belatacept is a selective costimulation blocker designed to provide effective immunosuppression while avoiding the toxicities associated with calcineurin inhibitors. Phase 3 trial data have demonstrated that belatacept is noninferior to cyclosporine in 1-year patient and allograft survival. Three-year data demonstrate an ongoing improvement in mean measured glomerular filtration rate in belatacept-treated versus cyclosporine-treated patients. Overall, there seemed to be an improvement in cardiometabolic parameters in patients treated with belatacept compared with cyclosporine. There was a trend toward higher rates of early rejection episodes in patients treated with belatacept. One safety issue that must be considered when using belatacept is the potential for increased risk of posttransplant lymphoproliferative disease, especially in Epstein-Barr virus-seronegative recipients or patients treated with lymphocyte-depleting agents. SUMMARY: Belatacept is the first new agent available in kidney transplant that may achieve the goal of improved long-term renal function.",
keywords = "belatacept, costimulation, kidney transplant",
author = "David Wojciechowski and Flavio Vincenti",
year = "2012",
month = "12",
day = "1",
doi = "10.1097/MOT.0b013e32835a4c0d",
language = "English (US)",
volume = "17",
pages = "640--647",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Belatacept in kidney transplantation

AU - Wojciechowski, David

AU - Vincenti, Flavio

PY - 2012/12/1

Y1 - 2012/12/1

N2 - PURPOSE OF REVIEW: In June 2011 the US Food and Drug Administration approved belatacept (Nulojix; Bristol-Myers Squibb, Princeton, New Jersey, USA) for the prophylaxis of organ rejection in adult kidney transplant recipients. This review will discuss the use of belatacept for the prevention of acute rejection as part of a maintenance immunosuppression regimen. RECENT FINDINGS: Belatacept is a selective costimulation blocker designed to provide effective immunosuppression while avoiding the toxicities associated with calcineurin inhibitors. Phase 3 trial data have demonstrated that belatacept is noninferior to cyclosporine in 1-year patient and allograft survival. Three-year data demonstrate an ongoing improvement in mean measured glomerular filtration rate in belatacept-treated versus cyclosporine-treated patients. Overall, there seemed to be an improvement in cardiometabolic parameters in patients treated with belatacept compared with cyclosporine. There was a trend toward higher rates of early rejection episodes in patients treated with belatacept. One safety issue that must be considered when using belatacept is the potential for increased risk of posttransplant lymphoproliferative disease, especially in Epstein-Barr virus-seronegative recipients or patients treated with lymphocyte-depleting agents. SUMMARY: Belatacept is the first new agent available in kidney transplant that may achieve the goal of improved long-term renal function.

AB - PURPOSE OF REVIEW: In June 2011 the US Food and Drug Administration approved belatacept (Nulojix; Bristol-Myers Squibb, Princeton, New Jersey, USA) for the prophylaxis of organ rejection in adult kidney transplant recipients. This review will discuss the use of belatacept for the prevention of acute rejection as part of a maintenance immunosuppression regimen. RECENT FINDINGS: Belatacept is a selective costimulation blocker designed to provide effective immunosuppression while avoiding the toxicities associated with calcineurin inhibitors. Phase 3 trial data have demonstrated that belatacept is noninferior to cyclosporine in 1-year patient and allograft survival. Three-year data demonstrate an ongoing improvement in mean measured glomerular filtration rate in belatacept-treated versus cyclosporine-treated patients. Overall, there seemed to be an improvement in cardiometabolic parameters in patients treated with belatacept compared with cyclosporine. There was a trend toward higher rates of early rejection episodes in patients treated with belatacept. One safety issue that must be considered when using belatacept is the potential for increased risk of posttransplant lymphoproliferative disease, especially in Epstein-Barr virus-seronegative recipients or patients treated with lymphocyte-depleting agents. SUMMARY: Belatacept is the first new agent available in kidney transplant that may achieve the goal of improved long-term renal function.

KW - belatacept

KW - costimulation

KW - kidney transplant

UR - http://www.scopus.com/inward/record.url?scp=84870251070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870251070&partnerID=8YFLogxK

U2 - 10.1097/MOT.0b013e32835a4c0d

DO - 10.1097/MOT.0b013e32835a4c0d

M3 - Review article

C2 - 23044530

AN - SCOPUS:84870251070

VL - 17

SP - 640

EP - 647

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 6

ER -